- Credit Amounts:
- Cost: Free
- Release: Sep 22, 2016
- Expires: Sep 22, 2017
Average User Rating:
Click Here to View All
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Professor and Chair
Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Division of Medical Oncology
Duke University Medical Center
Target AudienceThis activity is intended for clinical oncologists and other healthcare professionals who are involved in selecting therapeutic regimens for patients with NSCLC.
ObjectivesUpon completion of this activity, participants will be able to:
- Review the molecular pathology of lung cancer and examine its relevance for clinical practice.
- Outline the safety and efficacy of first-line therapies for advanced NSCLC, including first generation EGFR and ALK inhibitors.
- Evaluate treatment approaches used to overcome EGFR and ALK resistance in advanced NSCLC, including the safety and efficacy of second- and third-line therapies and recommended molecular testing.
- Appraise emerging concepts with EGFR TKIs and ALK inhibitors, including their role in adjuvant therapy, combination therapies, and other evolving data.
Faculty DisclosureIn accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Joan B. Fowler, PharmD, BCPP, has no relevant financial relationships to disclose in relation to the content of this activity.
Emir Hadzic, PhD, has no relevant financial relationships to disclose in relation to the content of this activity.
Pasi A. Jänne, MD, PhD (Activity Chair)
Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts
Disclosure: Dr. Jänne has disclosed that he is a consultant for AstraZeneca, Boehringer Ingelheim, Pfizer, Genentech, Roche, ARIAD, Chugai Pharmaceuticals, ACEA Biosciences, Merrimack Pharmaceuticals; receives grant/research support from Astellas and AstraZeneca; and receives other financial or material support from Gatekeeper Pharmaceuticals and LabCorp; post-marketing royalties from DFCI-owned intellectual property on EGFR mutations.
Tony S.K. Mok, BMSc, MD, FRCPC
Professor and Chair, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
Disclosure: Dr. Mok has disclosed that he is a consultant for ACA Biosciences, AstraZeneca, AVEO Oncology/Biodesix, BioMarin, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, geneDecode, GlaxoSmithKline, Janssen, Lilly, Merck Serono, MSD, Novartis, Pfizer, Roche/Genentech, SFJ Pharmaceuticals Group, and Vertex; is a major stock shareholder in Sanomics Ltd; and is a member of the speakers’ bureaus for Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, GlaxoSmithKline, Janssen, Lilly, MSD, Novartis, Pfizer, and Roche/Genentech.
Lecia V. Sequist, MD, MPH
Associate Professor of Medicine, Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Disclosure: Dr. Sequist has disclosed that she is a consultant for ARIAD, AstraZeneca, Boehringer Ingelheim, Clovis, Merrimack, Novartis, and Taiho.
Tom Stinchcombe, MD
Associate Professor, Division of Hematology and Oncology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Disclosure: Dr. Stinchcombe has disclosed that he is a consultant for ARIAD and Boehringer Ingelheim. He also receives grant/research support from Genentech.
AcknowledgmentSupported by an independent educational grant from AstraZeneca.
Instructions For Participation And CreditThere are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile